» Articles » PMID: 35336918

Enhanced SARS-CoV-2-Specific CD4 T Cell Activation and Multifunctionality in Late Convalescent COVID-19 Individuals

Abstract

Background: Examination of CD4+ T cell responses during the natural course of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection offers useful information for the improvement of vaccination strategies against this virus and the protective effect of these T cells. Methods: We characterized the SARS-CoV-2-specific CD4+ T cell activation marker, multifunctional cytokine and cytotoxic marker expression in recovered coronavirus disease 2019 (COVID-19) individuals. Results: CD4+ T-cell responses in late convalescent (>6 months of diagnosis) individuals are characterized by elevated frequencies of activated as well as mono, dual- and multi-functional Th1 and Th17 CD4+ T cells in comparison to early convalescent (<1 month of diagnosis) individuals following stimulation with SARS-CoV-2-specific antigens. Similarly, the frequencies of cytotoxic marker expressing CD4+ T cells were also enhanced in late convalescent compared to early convalescent individuals. Conclusion: Our findings from a low-to middle-income country suggest protective adaptive immune responses following natural infection of SARS-CoV-2 are elevated even at six months following initial symptoms, indicating the CD4+ T cell mediated immune protection lasts for six months or more in natural infection.

Citing Articles

COVID-19 and the Immune Response: A Multi-Phasic Approach to the Treatment of COVID-19.

Sapir T, Averch Z, Lerman B, Bodzin A, Fishman Y, Maitra R Int J Mol Sci. 2022; 23(15).

PMID: 35955740 PMC: 9369212. DOI: 10.3390/ijms23158606.

References
1.
Maione F, Casillo G, Raucci F, Salvatore C, Ambrosini G, Costa L . Interleukin-17A (IL-17A): A silent amplifier of COVID-19. Biomed Pharmacother. 2021; 142:111980. PMC: 8318692. DOI: 10.1016/j.biopha.2021.111980. View

2.
Guan W, Zhong N . Clinical Characteristics of Covid-19 in China. Reply. N Engl J Med. 2020; 382(19):1861-1862. DOI: 10.1056/NEJMc2005203. View

3.
Sekine T, Perez-Potti A, Rivera-Ballesteros O, Stralin K, Gorin J, Olsson A . Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19. Cell. 2020; 183(1):158-168.e14. PMC: 7427556. DOI: 10.1016/j.cell.2020.08.017. View

4.
Grifoni A, Weiskopf D, Ramirez S, Mateus J, Dan J, Rydyznski Moderbacher C . Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. Cell. 2020; 181(7):1489-1501.e15. PMC: 7237901. DOI: 10.1016/j.cell.2020.05.015. View

5.
Rydyznski Moderbacher C, Ramirez S, Dan J, Grifoni A, Hastie K, Weiskopf D . Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity. Cell. 2020; 183(4):996-1012.e19. PMC: 7494270. DOI: 10.1016/j.cell.2020.09.038. View